Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Jun;14(5):355-67.
doi: 10.1016/j.cardfail.2008.02.005. Epub 2008 May 27.

Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure

Roger J Hajjar  1 , Krisztina Zsebo, Lawrence Deckelbaum, Craig Thompson, Jeff Rudy, Alex Yaroshinsky, Hung Ly, Yoshiaki Kawase, Kim Wagner, Kenneth Borow, Brian Jaski, Barry London, Barry Greenberg, Daniel F Pauly, Richard Patten, Randall Starling, Donna Mancini, Mariell Jessup
Affiliations
Clinical Trial

Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure

Roger J Hajjar et al. J Card Fail. 2008 Jun.

Abstract

Background: Heart failure (HF) remains a major cause of morbidity and mortality in North America. With an aging population and an unmet clinical need by current pharmacologic and device-related therapeutic strategies, novel treatment options for HF are being explored. One such promising strategy is gene therapy to target underlying molecular anomalies in the dysfunctional cardiomyocyte. Prior animal and human studies have documented decreased expression of SERCA2a, a major cardiac calcium cycling protein, as a major defect found in HF.

Methods and results: We hypothesize that increasing the activity of SERCA2a in patients with moderate to severe HF will improve their cardiac function, disease status, and quality of life. Gene transfer of SERCA2a will be performed via an adeno-associated viral (AAV) vector, derived from a nonpathogenic virus with long-term transgene expression as well as a clinically established favorable safety profile.

Conclusions: We describe the design of a phase 1 clinical trial of antegrade epicardial coronary artery infusion (AECAI) administration of AAVI/SERCA2a (MYDICAR) to subjects with HF divided into 2 stages: in Stage 1, subjects will be assigned open-label MYDICAR in one of up to 4 sequential dose escalation cohorts; in Stage 2, subjects will be randomized in parallel to 2 or 3 doses of MYDICAR or placebo in a double-blinded manner.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources

-